Monitor clinical trial progress for GlyphAllo (topline data expected first half 2027) and GlyphAgo (topline data expected 2028), as these will be key catalysts for valuation. Track enrollment in the Phase 2b BUOY-1 trial, as delays could impact timelines. Watch for any regulatory feedback on trial design, particularly regarding the registration-enabling status of the BUOY-1 trial.
Executive Summary
Seaport Therapeutics is an IPO for a clinical-stage biotech company developing novel neuropsychiatric treatments using its proprietary Glyph platform to enhance drug bioavailability. The company is raising $183.5 million (up to $211.4 million with greenshoe) to advance its lead candidates, GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder, through clinical trials. The offering is priced at $16-$18 per share, with strong investor interest including a $50 million indication of interest from General Atlantic.
Key Financial Metrics
Key Facts
- Company is a clinical-stage therapeutics firm focused on depression and anxiety disorders using its proprietary Glyph platform to overcome first-pass metabolism issues.
- Lead product candidate GlyphAllo is in a Phase 2b trial for MDD with topline data expected in first half of 2027.
- Second candidate GlyphAgo showed 6.8-fold increase in bioavailability in Phase 1 trials and is advancing to Phase 2 trials for GAD.
- Company raised $325 million in private funding from top investors including General Atlantic, ARCH Venture Partners, and PureTech.
- IPO is offering 11.8 million shares at $16-$18 per share, with potential net proceeds of $183.5 million ($211.4 million with full greenshoe).
- Strong investor demand with $50 million indication of interest from General Atlantic and 5% directed share program for employees.
Financial Impact
$183.5 million in net proceeds (up to $211.4 million with greenshoe) at $17 midpoint pricing
Risk Factors
- Clinical-stage company with no revenue and significant operating losses ($74.9 million net loss in 2025)
- Heavy dependence on success of GlyphAllo and GlyphAgo, with no guarantee of regulatory approval
- Need for substantial additional funding beyond this offering to complete development programs
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-178716 |
| Document: d73463dex11.htm | 0001193125-26-178716 |
| Document: d73463dex102.htm | 0001193125-26-178716 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $20.65 $21.51 | ▲ +4.16% | ▲ +2.38% | $21.28 (+3.05%) |
Jun 8, 2026 20w ago | 8-K | $16.20 $23.61 | ▲ +45.74% | ▲ +42.69% | $21.28 (+31.36%) |
May 6, 2026 24w ago | 3 | $15.50 $20.65 | ▲ +33.23% | ▲ +29.39% | $21.28 (+37.29%) |
May 1, 2026 25w ago | 424B4 | $17.00 $19.74 | ▲ +16.12% | ▲ +14.26% | $21.28 (+25.18%) |
Apr 30, 2026 25w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $21.28 (+7.26%) |
Apr 30, 2026 25w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $21.28 (+7.26%) |
Apr 30, 2026 25w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $21.28 (+7.26%) |
Apr 30, 2026 25w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $21.28 (+7.26%) |
Apr 30, 2026 25w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $21.28 (+7.26%) |
Apr 27, 2026 26w ago | S-1/A | — | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers